101 stories found
Federal filings show directors and executives at Profrac, Boston Scientific, Northpointe Bancshares and Bankwell recently purchased company stock, with individual buys from $100,407 to $2.87 million.
A major cyberattack has triggered significant global operational disruptions, prompting a sharp decline in Boston Scientific's stock price as markets react to the incident.
Market analysts are comparing the recent sharp decline in Boston Scientific's stock price following a major cyber incident to historical sell-offs in the medical technology sector, assessing the long-term financial impact.
Investors are evaluating whether to continue holding Boston Scientific stock in anticipation of its upcoming device releases.
Boston Scientific (BSX) is reportedly experiencing a slowdown in growth across several of its core business segments, raising concerns about its future performance.
This report examines the target price set by Wall Street analysts for Boston Scientific stock, providing insights into their expectations for the medical technology company's future performance.
Boston Scientific reported positive Q2 results and expects 5-6% organic revenue growth, along with $500 million in run-rate savings by 2029. Idex also raised its organic growth outlook to 5-6% and forecasts 2026 adjusted EPS of $8.70 to $8.85.
Boston Scientific's stock has experienced a decline after its financial outlook fell short of market consensus expectations.
Boston Scientific anticipates headcount reductions as part of a broader restructuring initiative aimed at streamlining operations.
Boston Scientific has successfully had a $42 million patent verdict related to stents reversed, marking a significant legal development for the company.
Jefferies has significantly cut its price target for Boston Scientific (BSX). This adjustment prompts questions about the stock's investment appeal following the analyst's revised outlook.
TD Cowen has maintained its 'Buy' rating for Boston Scientific (BSX), indicating continued confidence in the company's stock performance.
Truist has lowered its target for Boston Scientific as doctors are reportedly changing how they utilize the company's heart devices.
BTIG analysts maintain a bullish outlook on Boston Scientific (BSX) stock, providing insights into their assessment of the company's performance and market position.
Boston Scientific has announced plans to build a new distribution center in Indiana, expanding its logistical capabilities in the region.
Wolfe Research has downgraded its rating for Boston Scientific Corporation (BSX) to 'Peer Perform' from its previous assessment.
A new device developed by Boston Scientific has demonstrated success in over 93% of patients during its pivotal clinical trial.
Bank of America has made several adjustments to its price targets for major companies, including a blunt call on HOKA-parent Deckers stock, a cut for Boston Scientific, and an increase for Apple due to an AI boost.
Financial firm Baird reiterated its bullish stance on Boston Scientific (BSX) stock, despite adjusting its price target lower.
Boston Scientific shares experienced a rise following the announcement of a $2 billion share buyback program and an investment in MiRus.
Boston Scientific (BSX) stock experienced a decline as investors raised concerns regarding the durability of the company's growth prospects.
An analysis evaluates whether Boston Scientific Corporation (BSX) is currently among the leading medical device stocks for investment. The article assesses its market position and potential.
Stephen Mandel's investment firm has reportedly opened a new position in Boston Scientific Corporation (BSX), a prominent medical device company.
Despite a recent disappointing performance, Boston Scientific (BSX) stock is being eyed for a potential comeback.
Boston Scientific reported steady performance for the first quarter of 2026 but adjusted its full-year 2026 outlook.
Boston Scientific has projected an organic growth rate of 6.5% to 8% through 2026. This forecast comes alongside a revised outlook for its Electrophysiology (EP) and WATCHMAN product lines.
Mizuho has lowered the price target for Boston Scientific Corporation in anticipation of the company's first-quarter medical device earnings report.
Boston Scientific has announced that its Asurys Fluid Management System has received clearance from the U.S. Food and Drug Administration (FDA).
Boston Scientific announced that its CHAMPION-AF clinical trial successfully met all primary endpoints. This positive outcome is significant for the medical device company and its ongoing research in cardiovascular health.
Several stocks, including Fannie Mae, Boston Scientific, Blackstone, and Palo Alto Networks, are experiencing the largest movements in midday trading.
An analysis suggests that a recent dip in Boston Scientific's stock price could represent a significant buying opportunity for investors.
Boston Scientific was aware of pacemaker battery issues for years, despite announcing multiple recalls and stating that battery problems were limited, with one internal test in 2025 revealing an "extremely high failure rate."
Boston Scientific (BSX) has raised its share buyback authorization to $5 billion, signaling confidence in its financial position and a move to return value to shareholders.
An article explains why Boston Scientific Corporation (BSX) is currently highly favored by hedge funds.
Medical device manufacturer Boston Scientific saw its stock decline after announcing a cybersecurity incident alongside a voluntary product recall affecting patient safety.
Medical device manufacturer Boston Scientific reported that a cyberattack has disrupted its global operations and triggered a recall of certain cardiac devices. The incident caused a sharp decline in the company’s stock price as investors assess the operational and financial impact.
Medical device manufacturer Boston Scientific confirmed that a recent cybersecurity breach temporarily halted internal order processing and logistics operations.
Boston Scientific reported a 21% increase in its Irish profits last year, reaching $135.72 million, following a significant investment in its Galway operations earlier this year.
Boston Scientific CEO Mahoney purchased more than 200,000 shares of the company's stock for $10 million, prompting investor speculation about future implications.
The US Federal Reserve maintained interest rates despite high inflation, with Chairman Warsh facing scrutiny over the decision. Meanwhile, Meta's AI strategy and future revenue projections are causing investor concern.
Medical device manufacturer Boston Scientific has informed the Irish government about potential job reductions at its operations in the country.
Boston Scientific has once again cut its financial guidance for 2026, indicating revised expectations for its future performance.
UBS has reportedly cut its target price for Boston Scientific but continues to recommend the stock as a 'buy'.
Boston Scientific (BSX) is experiencing a slowdown in its WATCHMAN device sales. Despite this, analysts continue to see potential upside for the company's stock.
Stifel has announced a reduction in its price target for Boston Scientific Corporation (BSX), with the reasons for this adjustment being outlined.
Piper Sandler has reiterated its 'Overweight' rating for Boston Scientific (BSX), signaling continued confidence in the medical technology company's stock.
Boston Scientific (BSX) experienced pressure in Q1 due to an outlook that fell below market expectations, impacting its financial performance.
Analysts are evaluating Boston Scientific and Medline as leading healthcare stocks with significant upside potential. These companies are being considered among the best investment opportunities in the healthcare sector.
Boston Scientific Corporation (BSX) is being highlighted as a potentially undervalued stock with strong buy ratings from Wall Street analysts.
Analysis of unusual options activity indicates that Boston Scientific stock may be a prime candidate for a merger and acquisition.
Boston Scientific's stock saw a significant drop after the company reiterated its full-year growth guidance, which was perceived as underwhelming by investors.
A summary of significant healthcare news for the week, highlighting companies like UnitedHealth, Boston Scientific, and Eli Lilly.
An analysis questions whether Boston Scientific (BSX) stock represents a value trap or a potential rebound opportunity for investors.
Boston Scientific has made a significant investment of $1.5 billion in MiRus, acquiring approximately a 34% equity stake in the company.
Billionaire investor Tom Steyer has reportedly increased his holdings in several companies, including tech giants like Microsoft and Amazon, and various pharmaceutical firms. His recent investment activities indicate a bullish outlook on these specific stocks.
The article explores the differing opinions among Wall Street analysts regarding the future performance and outlook of Boston Scientific stock, questioning whether sentiment is bullish or bearish.
Polen Focus Growth, an investment fund, sold its holdings in both Abbott Laboratories and Boston Scientific during the first quarter. The fund cited competition concerns as a reason for divesting its stake in Boston Scientific.
Boston Scientific has significantly lowered its financial guidance, leading to a market pullback. Analysts are now evaluating whether the resulting dip in stock price presents a buying opportunity for investors.
Tesla reported first-quarter earnings that surpassed analyst expectations, leading to a surge in its stock price. The automaker attributed its strong performance to increased deliveries and a rebound in demand for electric vehicles, alongside a pivot towards AI and robotics.
Boston Scientific has announced a reduction in its financial guidance for 2026. This revision may impact investor expectations and the company's future outlook.
Leerink has reiterated an Outperform rating on Boston Scientific (BSX) following the CHAMPION-AF readout.
An analysis examines the potential for Boston Scientific stock to surge by 40% from its current position.
An article provides an outlook on what to anticipate from Boston Scientific's first-quarter 2026 earnings report.
Truist has lowered its price target for Boston Scientific Corporation (BSX) from $95 to $92, citing specific reasons for the adjustment.
The article explores Wall Street's current sentiment and outlook regarding Boston Scientific Corporation (BSX).
This cluster includes news on analyst ratings, significant investment filings, regulatory compliance, proposed rights issues, and new business orders for individual companies.
Investment commentary explores whether the medical device maker’s depressed share price presents an attractive opportunity for income-focused investors.
Shares of medical device manufacturer Boston Scientific have dropped sharply after the company disclosed a widespread cybersecurity breach that temporarily disrupted its global operations. The incident has raised investor concerns regarding the firm's digital infrastructure and operational resilience.
Shares of Boston Scientific are approaching a critical support threshold, prompting investor scrutiny over whether the stock can maintain its current valuation levels.
Boston Scientific (BSX) is reportedly facing growth concerns within its key medical device franchises.
Plans for workforce reduction at Boston Scientific's Clonmel facility, which employs around 1,200 people, have prompted concern in Tipperary.
A summary of Boston Scientific Corporation's second-quarter 2026 earnings call has been published, outlining the company's financial results and future projections.
Boston Scientific has cut its profit forecast for Q2 2026, citing a slowdown in sales of its Watchman device.
Boston Scientific has revised its annual profit forecast downwards, citing softer demand for its Watchman device. The adjustment reflects changing market conditions for the medical device company.
Boston Scientific has announced the initiation of a new restructuring plan, indicating strategic changes within the company's operations and expecting job cuts as part of the process.
D. E. Shaw's investment portfolio includes several prominent technology and AI-related companies. Among their top holdings are Meta Platforms, Micron Technology, Boston Scientific, Apple, Alphabet, and NVIDIA.
This analysis evaluates whether Novo Nordisk (NVO) and Boston Scientific (BSX) are among the best low volatility stocks to consider buying for under $50.
Jim Cramer provided varied investment advice on several companies, expressing skepticism about stocks like McGraw Hill, Boston Scientific, and Rivian, while recommending Madison Square Garden Sports and maintaining a positive outlook on SoFi.
Truist has reiterated its 'Buy' rating for both Meta Platforms (META) and Boston Scientific (BSX). The firm set a price target of $840 for Meta Platforms.
Several businesses and agencies in Ireland, including EY and Boston Scientific, are offering paid graduate programs to new professionals.
Jim Cramer offered his insights on Boston Scientific and other medical equipment manufacturers. His commentary provides an overview of his views on the performance and investment potential within the medical technology sector.
Boston Scientific's stock experienced a decline this week, with reasons for the drop being analyzed.
Boston Scientific is making a significant $1.5 billion investment in a large market, drawing attention from Wall Street.
Boston Scientific Corporation (BSX) experienced a decline in its stock value following the release of weaker-than-expected financial results.
Boston Scientific announced that its SEISMIQ 4CE device successfully completed trials for treating coronary artery disease.
Financial commentator Jim Cramer has provided a range of stock recommendations, advising on whether to buy, hold, or avoid various companies including TJX, Caterpillar, Eli Lilly, and Cloudflare. He also expressed regret over selling Cisco and cautioned against buying certain stocks at their current highs.
Boston Scientific's Annual General Meeting revealed a $20 billion sales target for 2025, with governance votes passing while special meeting proposals failed.
Jim Cramer offered his assessment of Boston Scientific, suggesting that the company has the potential to 'come back' in the market.
A compilation of top Wall Street analyst research calls for Wednesday includes recommendations for major companies such as Alibaba, Boston Scientific, Brown-Forman, Charter Communications, Franklin Resources, Spotify, and T-Mobile, among others. This provides an overview of market sentiment on various stocks.
Wall Street analysts have released their top research calls for Thursday, covering companies such as Boston Scientific, Datadog, McDonald's, and Palantir Technologies.
Boston Scientific's stock saw a significant jump on April 22 after the company reported better-than-expected Q1 earnings, leading to a reset of growth expectations.
Truist has lowered its price target for Boston Scientific Corporation (BSX) from $92 to $90.
Citi has reiterated its 'Buy' rating for Boston Scientific (BSX).
Boston Scientific has finalized its buyout of Valencia Technologies, completing a significant corporate acquisition.
Boston Scientific's stock experienced a decline after the release of data concerning its Watchman device, which is used for stroke reduction.
An analysis evaluates whether Boston Scientific Corporation (BSX) stock presents a good investment opportunity at the current time.
Financial commentator Jim Cramer discusses Boston Scientific, noting that while it was once a top performer, its stock performance has since declined.
An analysis suggests that Boston Scientific stock could see significant growth, potentially increasing fivefold, driven by the global aging population.